Lung cancer tester Biodesix makes preliminary IPO filing

BOULDER — Lung-cancer genetics tester Biodesix Inc. has filed a preliminary prospectus for an initial public offering.

In filings with the U.S. Securities and Exchange Commission Friday afternoon, the Boulder company said it plans to go public in the Nasdaq Global Market under the symbol “BDSX.”

The filing is preliminary and lacks key information such as the amount of money it is looking to raise, the target range for its stock price at debut and the timing of those stocks hitting the open market.

Biodesix creates tests that analyze lung-cancer samples to…